Skip to main content
Health & Wellness

Lp(a) Test: What the Failed Pelacarsen Trial Means

A drug cut Lp(a) 78% yet heart attacks did not fall. Here is what the Lp(a) test still tells you, how to read your result, and what to do if it comes back high.

Priya Raman
November 17, 20269 min read
Share
Lp(a) Test: What the Failed Pelacarsen Trial Means
Table of contents

Your cholesterol numbers look fine. Your LDL is low, you take your statin, and your blood pressure behaves. Then a cardiologist orders an Lp(a) test, and the result comes back flagged high. You ask what pill fixes it, and the honest answer is that none does yet.

For years, that answer came with a hopeful footnote: drugs were coming. On November 7, the first of them failed its big test. A Novartis drug called pelacarsen cut lipoprotein(a) by about 78% in more than 8,300 heart patients, yet heart attacks, strokes and deaths did not budge.

So is the Lp(a) test now pointless? Cardiologists say no, and the reasons are practical. This guide walks through what the trial found, what it can and cannot prove, and how to read your own number.

What the Lp(a)HORIZON Trial Actually Tested

Lipoprotein(a), usually written Lp(a), is a cholesterol-carrying particle that behaves a lot like LDL. It can help build plaque in artery walls. Unlike LDL, your Lp(a) level is set mostly by your genes and stays fairly stable for life.

Pelacarsen is an antisense drug. It enters liver cells and blocks them from making the protein that forms Lp(a). Patients injected 80 mg under the skin once a month.

The trial was large and long. According to the trial paper in the New England Journal of Medicine, 8,350 patients were randomized, with 4,157 on pelacarsen and 4,165 on placebo in the efficacy analysis. The American Heart Association says they came from 797 sites in 42 countries.

  • Who joined: adults with an earlier heart attack, stroke or leg artery disease, and Lp(a) of at least 70 mg/dL.
  • Average patient: 59.7 years old, and 27% were women.
  • Starting Lp(a): a median of 236 nmol/L, well above common risk cutoffs.
  • Already well treated: roughly 78% took high-intensity statins, and about three in four already met cholesterol and blood pressure targets.

The main goal was simple. Researchers counted the first major heart event: cardiovascular death, a nonfatal heart attack, a nonfatal stroke, or an urgent procedure to reopen a blocked heart artery.

Why a 78% Drop Did Not Prevent Heart Attacks

The drug did exactly what it was built to do. At 12 months, median Lp(a) sat at 64.4 nmol/L in the pelacarsen group and 233.4 nmol/L on placebo. Then the outcome numbers arrived.

A major heart event hit 511 people on pelacarsen (12.3%) and 503 on placebo (12.1%). The hazard ratio was 1.02, with a 95% confidence interval of 0.90 to 1.15. Put plainly, there was no difference. Patients with the highest levels, at least 90 mg/dL, fared no better: 12.3% in both groups.

Steven Nissen of Cleveland Clinic, the senior author, told the American Heart Association newsroom, "I cannot avoid the disappointing conclusion, it didn't work."

What the trial can show

It shows that this drug, at this dose, given to people who already had heart disease and were already well treated, did not cut events over about five years. That is a solid finding from a randomized, placebo-controlled design, the strongest kind of evidence.

What it cannot show

It cannot show that Lp(a) is harmless, or that every Lp(a) drug will fail. Experts quoted by TCTMD, the cardiology news site, offered several possible reasons:

  • Too little room to improve. Average LDL was about 65 mg/dL and systolic blood pressure about 125, so other risks were already tightly controlled.
  • Too late in the disease. Patients may have had advanced plaque that a few years of treatment could not reverse.
  • Too short. High Lp(a) is a lifelong exposure, and 4.7 years may not offset decades of it.
  • Side effects. Drug-related adverse events hit 56.8% of pelacarsen patients versus 18.0% on placebo.

Why the Lp(a) Test Still Matters

Here is the part that surprises people. The same experts who ran the failed trial still want you tested. The Lp(a) test measures risk, and that risk did not disappear because one drug missed.

The numbers behind that view come from population studies, not from this trial. The AHA says about 1 in 5 people worldwide, roughly 1.4 billion, have elevated Lp(a). Levels of 125 nmol/L or higher carry about 1.4 times the long-term risk of heart attack or stroke. At 250 nmol/L or higher, that risk at least doubles.

Three facts make the test unusual:

  • You usually only need it once. Because genes set the level, the newest multi-society cholesterol guideline recommends measuring Lp(a) at least once in adulthood.
  • A normal cholesterol panel misses it. High Lp(a) causes no symptoms and does not show up in a standard lipid test.
  • Ancestry matters. The AHA notes that people of African ancestry have average Lp(a) about twice that of white people, yet fewer than 4% of trial participants were of African ancestry.

Cardiologist Donald Lloyd-Jones told TCTMD the guideline advice to test once still stands. A high result can tip a borderline decision, such as whether to start a statin or how low to push your LDL. That is the practical value today, with or without a dedicated drug.

How to Read Your Lp(a) Test Result

Labs report Lp(a) in two different units, and that trips up many readers. Some use milligrams per deciliter (mg/dL). Others use nanomoles per liter (nmol/L), which counts particles. There is no exact conversion, because Lp(a) particles vary in size, so the AHA lists approximate pairs.

Use these reference points from the AHA and the trial:

  • About 55 mg/dL, or 125 nmol/L: roughly 1.4 times the long-term heart risk.
  • About 70 mg/dL, or 148 nmol/L: the entry floor for Lp(a)HORIZON.
  • About 90 mg/dL, or 192 nmol/L: roughly the top 15% of people with high levels.
  • About 115 mg/dL, or 250 nmol/L: at least double the long-term risk.

A worked example

Say your report reads 62 mg/dL. That sits above the 55 mg/dL line tied to about 1.4 times the risk, but below the 115 mg/dL line where risk doubles. Your brother tests at 260 nmol/L, which clears the 250 nmol/L mark. His result points to at least twice the long-term risk of someone with low Lp(a).

Now picture what the trial meant in those terms. Per 1,000 patients, about 123 on pelacarsen and 121 on placebo had a major event. A drug that cut Lp(a) from 236 to 64 nmol/L did not move that count at all.

Your number tells you about risk, not about a treatment that exists today. Bring both units to your doctor if your lab printed them.

What You Can Do With a High Lp(a) Result Now

A high number with no approved drug can feel like bad news you cannot act on. That is not quite true. The lever you control is everything else on your risk sheet. The AHA says exercise, diet and statins have little effect on Lp(a) itself, but they still lower your total risk.

  1. Push LDL cholesterol lower with your doctor. Ask whether your Lp(a) result changes your LDL target. If you are older and weighing your statin, our look at what a new trial shows about stopping statins after 70 covers that tradeoff.
  2. Get blood pressure under control. It is one of the few risks you can move within weeks. If you take two pills now, our guide weighs one combined blood pressure pill against two separate ones.
  3. Tell your family. Lp(a) is inherited, so a parent, sibling or adult child may carry the same high level. The Family Heart Foundation urges people to learn their relatives' numbers.
  4. Ask about clinical trials. Other drugs are still being tested in outcome trials: olpasiran in OCEAN(a)-Outcomes and OCEAN(a)-PreEvent, lepodisiran in ACCLAIM-Lp(a), and muvalaplin in MOVE-Lp(a).

Those newer drugs are not copies of pelacarsen. Nissen said small interfering RNA (siRNA) drugs, a different class now in testing, may lower Lp(a) further and cause fewer side effects. Some of those trials also enroll people who have not yet had a heart attack, the group pelacarsen never tested.

Novartis has dropped the pelacarsen heart disease program, according to TCTMD. Clots are a separate risk with their own new drugs, covered in our piece on the new stroke prevention pill asundexian.

Frequently Asked Questions

Is an Lp(a) test worth getting if there is no drug for it?

Most cardiologists say yes. The current US guideline recommends one Lp(a) test in adulthood, because a high result can change how aggressively your doctor treats LDL cholesterol and blood pressure. You usually need the test only once, since your genes set the level.

What is a normal Lp(a) level?

The AHA links levels of about 125 nmol/L (55 mg/dL) or higher with roughly 1.4 times the long-term risk of heart attack or stroke. At 250 nmol/L (115 mg/dL) or higher, the risk is at least double. Check which unit your lab uses before comparing your result.

Can diet or exercise lower Lp(a)?

Not by much. The AHA says exercise, diet and statins have little effect on Lp(a) because genes largely set it. Those habits still lower your overall heart risk, which is why doctors focus on them when Lp(a) is high.

Why did pelacarsen fail if it lowered Lp(a)?

Nobody knows yet. Experts have raised several possibilities: patients already had very low LDL and well controlled blood pressure, many may have had advanced plaque, and 4.7 years may be too short to undo lifelong exposure. About 21% of pelacarsen patients also stopped the drug because of side effects, versus about 7% on placebo.

Should I drop out of an Lp(a) drug trial after this result?

Talk to your study team before making any change. Nissen told the AHA he would advise anyone in a different Lp(a) trial not to drop out, because those drugs work differently and still need answers. If you were in a pelacarsen study, the Family Heart Foundation says to contact your study team for guidance.

The Bottom Line on Your Lp(a) Number

Lp(a)HORIZON closed one door. A drug that slashed Lp(a) by about 78% did not reduce heart events in people who already had heart disease. It did not close the question of whether Lp(a) drives heart disease, and it says nothing about prevention in healthy people.

If you have never had an Lp(a) test, ask about it at your next checkup. If yours is already high, treat it as a reason to work harder on LDL and blood pressure with your doctor, and to tell your relatives. The next answers should come from the siRNA trials now running.

Share

Written by

Priya Raman

Health & Living

Covers health, wellness, and everyday living for Quick Trend Insights, with an interest in separating what the research supports from what the marketing claims.

More articles

Related Articles

View all